Cross Staff Investments Inc Takes Position in Enovis Co. (NYSE:ENOV)

Cross Staff Investments Inc purchased a new position in shares of Enovis Co. (NYSE:ENOV) during the 4th quarter, HoldingsChannel reports. The firm purchased 3,666 shares of the company’s stock, valued at approximately $205,000.

A number of other hedge funds also recently bought and sold shares of the stock. Fifth Third Bancorp grew its stake in shares of Enovis by 144.6% during the third quarter. Fifth Third Bancorp now owns 587 shares of the company’s stock worth $31,000 after purchasing an additional 347 shares in the last quarter. UMB Bank n.a. acquired a new position in shares of Enovis during the 3rd quarter worth about $31,000. First Horizon Advisors Inc. increased its holdings in shares of Enovis by 902.7% in the 3rd quarter. First Horizon Advisors Inc. now owns 732 shares of the company’s stock valued at $39,000 after acquiring an additional 659 shares during the last quarter. GAMMA Investing LLC acquired a new stake in shares of Enovis during the 4th quarter worth about $53,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Enovis during the third quarter worth approximately $82,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of NYSE:ENOV traded up $0.13 during trading on Friday, reaching $55.23. The company had a trading volume of 176,879 shares, compared to its average volume of 453,907. The stock’s fifty day moving average price is $59.95 and its 200 day moving average price is $55.48. Enovis Co. has a fifty-two week low of $43.04 and a fifty-two week high of $66.14. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -90.28 and a beta of 1.97. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.43 and a quick ratio of 1.16.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.03. The business had revenue of $455.00 million for the quarter, compared to analysts’ expectations of $444.34 million. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. The business’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.72 EPS. As a group, equities research analysts predict that Enovis Co. will post 2.58 EPS for the current year.

Analyst Ratings Changes

ENOV has been the topic of a number of research analyst reports. Wells Fargo & Company raised their price objective on shares of Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Stephens started coverage on shares of Enovis in a research note on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price objective for the company. Canaccord Genuity Group lifted their target price on Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. William Blair assumed coverage on Enovis in a research report on Wednesday, January 3rd. They issued an “outperform” rating for the company. Finally, UBS Group started coverage on Enovis in a research report on Monday, January 22nd. They set a “buy” rating and a $75.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $75.43.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.